IN Brief:
- NAB-CCM’s roadmap targets inconsistent storage, handling, and distribution practices.
- Four stages cover training, vendor qualification, certification, auditing, and monitoring.
- Biologics and specialty medicines are increasing the cost of temperature excursions.
The National Accreditation Body for Cold Chain Management has published a four-stage roadmap for improving the storage and distribution of temperature-sensitive medicines across India, bringing training, operating standards, supplier qualification, monitoring, and regulatory oversight into a single programme.
The white paper, Strengthening Pharmaceutical Cold Chain Management in India, was developed through consultation with regulators, pharmaceutical manufacturers, healthcare institutions, logistics providers, packaging specialists, and academic organisations. Its recommendations address the uneven application of Good Storage and Distribution Practices across a network stretching from factories and central distribution centres to hospitals, pharmacies, laboratories, and local dispensing points.
Fragmentation remains one of the network’s defining weaknesses, because products may pass through several storage sites, transport providers, regional distributors, and healthcare facilities before reaching their point of use. Each transfer introduces another set of employees, procedures, equipment, and records, while responsibility for an excursion may become less clear as the number of handovers increases.
Under the roadmap’s first stage, the emphasis falls on awareness, professional training, competence development, and simplified operational guidance. Employees receiving, inspecting, storing, picking, loading, transporting, and dispensing temperature-sensitive products would work from a more consistent baseline, rather than leaving cold-chain control predominantly to quality-assurance teams.
A second stage would establish more structured vendor qualification, certification, and standardised monitoring. Pharmaceutical manufacturers frequently contract several companies across packaging, storage, transport, and final delivery, yet those suppliers may be assessed against different criteria or subjected to widely varying levels of audit. A common qualification framework would give procurement and quality teams a firmer basis for comparing providers.
The later stages extend the programme into wider industry adoption, formal auditing, compliance assessment, policy review, and greater use of connected monitoring. Real-time temperature and location data would provide earlier warning of developing problems, although a sensor alert remains useful only when responsibilities, escalation routes, stability information, and product-disposition procedures are already defined.
Specialist infrastructure has continued to expand around India’s pharmaceutical clusters. Kuehne+Nagel’s temperature-controlled operation in Hyderabad added capacity close to one of the country’s principal life-sciences manufacturing centres, while the NAP Pharma network has broadened access to validated healthcare-logistics services through independent forwarding partners.
Those investments strengthen controlled storage and transport, but the final stages of distribution remain difficult to standardise. Large logistics providers can operate validated warehouses, qualified vehicles, redundant refrigeration, calibrated monitoring devices, and controlled loading procedures, whereas smaller healthcare facilities may have more limited equipment, maintenance support, backup power, or cold-chain expertise.
Biologics, vaccines, insulin, and specialty medicines are steadily increasing the value exposed during each movement. Narrower temperature tolerances leave less room for delay or poor handling, while a rejected consignment removes scarce inventory from circulation, triggers a replacement movement, postpones treatment, and generates an investigation across several organisations.
As product complexity rises, lane qualification and packaging validation become more exacting. Transport plans must account for seasonal temperatures, airport or border dwell, vehicle breakdowns, delayed customs clearance, and the length of time a passive container can remain within specification. Procedures also need to distinguish between a momentary sensor fluctuation and an exposure capable of compromising the medicine.
Connected equipment can improve that evidence base when data is integrated into operational decisions. Similar principles are emerging in maritime temperature-controlled logistics, where Maersk is turning refrigerated containers into connected assets capable of transmitting condition and location information. Pharmaceutical applications require stricter validation and access controls, but both depend on reliable data reaching someone authorised to intervene.
Workforce competence carries equal weight, because equipment cannot compensate for a poorly managed handover. Receiving employees must recognise damaged packaging and incorrect logger status, warehouse teams require defined quarantine and segregation processes, drivers need escalation routes for delays or refrigeration faults, and dispensing sites must understand how long products may remain outside controlled storage.
Contracts and procurement processes offer one route towards faster adoption. Manufacturers and healthcare organisations can incorporate training standards, excursion-response times, calibration requirements, data access, supplier-audit rights, and continuity arrangements into logistics agreements, while certification could reduce repeated assessments where several customers currently audit the same provider separately.
Implementation will depend on whether the roadmap develops into recognised audit criteria, procurement requirements, and regulatory expectations rather than remaining voluntary guidance. India combines large-scale pharmaceutical production, a geographically extensive domestic market, and growing export activity, so consistent operating practice must survive every transfer between sophisticated manufacturing sites and a far more varied distribution network.
The four-stage structure acknowledges that cold-chain resilience cannot be purchased as a collection of refrigerated vehicles and data loggers. Training, supplier governance, infrastructure, monitoring, and regulatory alignment have to advance together if the condition of a medicine is to remain defensible from production line to patient.
